Gamida Cell Announces 2020 Goals and Provides Company Update
– Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing…
Pharmaceuticals, Biotechnology and Life Sciences
– Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing…
Harbert Repeatedly Demonstrates a Profound Lack of Understanding of Enzo’s Business and Sector Falsely Asserts Enzo Has Failed to Make…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced…
WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P.…
New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in…
MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development…
LAWRENCEVILLE, N.J. & Switzerland–(BUSINESS WIRE)–Adare Pharmaceuticals, Inc. (Adare) and NLS Pharmaceutics Ltd. (NLS) announced today a collaboration to develop mazindol…
VANCOUVER, British Columbia & FOUNTAIN VALLEY, Calif.–(BUSINESS WIRE)–#cancergenomics–Contextual Genomics, a leading cancer genomics company, and Lab Genomics, a personalized medicine…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today…
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage…